| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Medesis Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.52 |
| 52 Week High | €2.67 |
| 52 Week Low | €0.75 |
| Beta | -0.056 |
| 1 Month Change | -6.17% |
| 3 Month Change | 87.65% |
| 1 Year Change | -29.63% |
| 3 Year Change | -83.83% |
| 5 Year Change | n/a |
| Change since IPO | -85.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALMDP | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 14.3% | 2.0% | 1.2% |
| 1Y | -29.6% | -8.2% | 4.0% |
Return vs Industry: ALMDP underperformed the French Biotechs industry which returned -9.1% over the past year.
Return vs Market: ALMDP underperformed the French Market which returned 3.2% over the past year.
Price Volatility
| ALMDP volatility | |
|---|---|
| ALMDP Average Weekly Movement | 23.0% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALMDP's share price has been volatile over the past 3 months.
Volatility Over Time: ALMDP's weekly volatility has increased from 13% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 10 | Jean-Claude Maurel | www.medesispharma.com |
Medesis Pharma S.A. operates as a biopharmaceutical company. The company’s products include NanoLithium (NP03) for the treatment of Alzheimer’s disease; NanosiRNA HD and NanoP42T to treat Huntington’s disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma.
Medesis Pharma S.A. Fundamentals Summary
| ALMDP fundamental statistics | |
|---|---|
| Market cap | €6.73m |
| Earnings (TTM) | -€2.79m |
| Revenue (TTM) | €428.99k |
15.7x
P/S Ratio-2.4x
P/E RatioIs ALMDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALMDP income statement (TTM) | |
|---|---|
| Revenue | €428.99k |
| Cost of Revenue | €2.20m |
| Gross Profit | -€1.78m |
| Other Expenses | €1.02m |
| Earnings | -€2.79m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | -413.78% |
| Net Profit Margin | -650.48% |
| Debt/Equity Ratio | -97.6% |
How did ALMDP perform over the long term?
See historical performance and comparison